Sökning: id:"swepub:oai:DiVA.org:su-171702" >
Tau PET imaging in ...
Tau PET imaging in neurodegenerative tauopathies-still a challenge
-
Leuzy, Antoine (författare)
-
- Chiotis, Konstantinos (författare)
- Karolinska Institutet
-
- Lemoine, Laetitia (författare)
- Karolinska Institutet
-
visa fler...
-
- Gillberg, Per-Goran (författare)
- Karolinska Institutet
-
- Almkvist, Ove (författare)
- Stockholms universitet,Biologisk psykologi,Karolinska Institutet, Stockholm, Sweden
-
- Rodriguez-Vieitez, Elena (författare)
- Karolinska Institutet
-
- Nordberg, Agneta (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2019-01-11
- 2019
- Engelska.
-
Ingår i: Molecular Psychiatry. - : Springer Science and Business Media LLC. - 1359-4184 .- 1476-5578. ; 24:8, s. 1112-1134
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://www.nature.c...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is the most common. Related tauopathies include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), Down's syndrome (DS), Parkinson's disease (PD), and dementia with Lewy bodies (DLB). Investigation of the role of tau pathology in the onset and progression of these disorders is now possible due the recent advent of tau-specific ligands for use with positron emission tomography (PET), including first-(e.g., [F-18] THK5317, [F-18] THK5351, [F-18] AV1451, and [C-11] PBB3) and second-generation compounds [namely [F-18] MK-6240, [F-18] RO-948 (previously referred to as [F-18] RO69558948), [F-18] PI-2620, [F-18] GTP1, [F-18] PM-PBB3, and [F-18] JNJ64349311 ([F-18] JNJ311) and its derivative [F-18] JNJ-067)]. In this review we describe and discuss findings from in vitro and in vivo studies using both initial and new tau ligands, including their relation to biomarkers for amyloid-beta and neurodegeneration, and cognitive findings. Lastly, methodological considerations for the quantification of in vivo ligand binding are addressed, along with potential future applications of tau PET, including therapeutic trials.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Psykiatri (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Psychiatry (hsv//eng)
Nyckelord
- tau
- PET
- tauopathies
- Alzheimer's disease
- PSP
- CBS
- DS
- PD
- DLB
- amyloid-β
- neurodegeneration
- cognitive findings
- in vivo ligand binding
- Psychology
- psykologi
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas